Media Coverage

Delivering a vaccine for a global pandemic that has caused nearly 1.5 million deaths and has infected more than 64 million people – as of early December 2020 – will require a logistical effort of extraordinary complexity. In the following Q&A, Associate Professor Tinglong Dai of the Johns Hopkins Carey Business School offers insights into the process of administering COVID-19 vaccines in the United States as well as in other parts of the world. Dai is an expert in operations management and business analytics, with a focus on the health care industry.

Reports of spiking COVID-19 cases and related fatalities have been met with recent news of extremely promising vaccines developed by Pfizer and Moderna. With the two offerings promising 90 and 95 percent effectiveness against the virus, respectively, attention now turns to mass production and, more importantly, mass distribution. According to Anna Nagurney, Ph.D., Director of the Virtual Center for Supernetworks and professor at the Department of Operations and Information Management at the University of Massachusetts, distribution is where the biggest challenges lie.

With COVID-19 cases rising across the country, the need for a safe and reliable vaccine is increasing. Both Pfizer and Moderna have announced vaccine trials with more than 90% effectiveness. Creating vaccines and getting federal approval are only the first hurdles which are followed by finding ways to transport the highly-perishable vaccines to millions of Americans.

Upwards of 267,000 people have so far died in the U.S. from the novel coronavirus, and experts have fatalistic predictions about more infections throughout the winter. But it’s not just the coronavirus that’s killing people. University of Illinois at Urbana-Champaign computer scientist Sheldon Jacobson and Dr. Janet Jokela, acting dean of the University of Illinois College of Medicine at Urbana, examined Centers for Disease Control and Prevention data from March through May, the period early in the pandemic when states like Illinois had stay-at-home orders in effect.

Hot-spot Midwestern states have reported modest declines in new daily COVID-19 cases over the past few days, but epidemiologists have warned against taking this as a sign that the surge is over. “I think it is premature to feel that we turned the corner until we see at least a week or two to have sort of [a] decline,” said Dr. Oguzhan Alagoz, an expert in healthcare analytics at the University of Wisconsin-Madison.